I have had the great privilege of serving my local health system as Medical Director for Home Hospice. Every week I sit in a ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target ...

Large pill size, high pill burden and palatability were identified as key barriers for phosphate binder adherenceLOS ALTOS, ...

Capital Markets increased its price target on Perspective Therapeutics Inc (NYSE:CATX) shares to $20.00, up from the previous $15.00, while maintaining a Buy rating on the stock. The $259.2 million ...

In a report released today, Nicole Germino from Truist Financial maintained a Buy rating on Perspective Therapeutics (CATX – Research Report).

Analysts have recently evaluated Sangamo Therapeutics and provided 12-month price targets. The average target is $8.09, accompanied by a high estimate of $10.00 and a low estimate of $2.00. Surpassing ...

Wedbush reissued their outperform rating on shares of Perspective Therapeutics (NYSE:CATX – Free Report) in a report released ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Perspective Therapeutics (CATX – Research ...